10/15/2026
- Rare Disease News -
The FDA has launched an initiative to develop a new regulatory framework designed around the unique realities of rare disease drug development. This includes those with limited natural history data and challenges with traditional clinical trial designs.
The goal is not to lower standards for safety or effectiveness, but to ensure the methods used to evaluate potential treatments are appropriate for rare diseases.
If successful, this could lead to more consistent and effective ways to develop new therapies treatment options for people living with rare diseases like .
Read more from National Organization for Rare Disorders, Inc. (NORD): https://tinyurl.com/2p54anaw
Statement from Pam Gavin, President and Chief Executive Officer